Supplement, Drug Co-Packaging Potential Could Be Clipped In FDA Proposed Rule
This article was originally published in The Rose Sheet
Innovus Pharmaceuticals is among the firms offering supplements and OTC drugs sold together, an option CRN encourages FDA to allow. FDA will determine on a case-by-case basis whether co-packaged OTCs and supplements already available are in violation of a proposed rule on drug co-packaging.
You may also be interested in...
Innovus acquires Boston Topicals' ThermoMax hand warming cream in hot and warm formulations, BreastLife with amino acids to firm and lift women's breasts and HealthiFeet made with Knosis transdermal delivery system in a formulation firm says has been shown in a trial to increase temperature and blood flow in feet of diabetic patients. HealthiFeet will complement a product Innovus already offers and targets for consumers with diabetes, Diabases leg and foot relief topical.
Sales of dietary supplements promoted as non-drug alternative remedies and stocked nearby OTC in stores grew almost 12% in 2017, says Kline analyst Laura Mahecha. Retailers began co-stocking the about five years ago but in many cases the supplements currently have primary placement on shelves.
Johnson & Johnson maintains hectic deal-making pace via RA tie-up with Monash and "diabesity" collaboration with UC San Diego.